4-(3-hydroxyphenylamino)-quinazoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(3-hydroxyphenylamino)-quinazoline
• 英文别名: (3-hydroxy-phenyl)-quinazolin-4-yl-amine；3-(4-Quinazolinylamino)phenol；3-(quinazolin-4-ylamino)phenol
• 化学式: C₁₄H₁₁N₃O
• 分子量: 237.261
• InChiKey: BLCNTDFTVUAJKY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  四氢吡咯 、 聚合甲醛 、 4-(3-hydroxyphenylamino)-quinazoline 以 乙醇 为溶剂， 反应 3.0h， 生成 4-<2,4-bis<(N-pyrrolidinyl)methyl>-3-hydroxyanilino>quinazoline
  参考文献：
  名称：

  Synthesis and antiarrhythmic and parasympatholytic properties of substituted phenols. 1. Heteroarylamine derivatives

  摘要：

  Twenty-four structural derivatives of the antiarrhythmic drug changrolin were synthesized and tested for antiarrhythmic and parasympatholytic activities. It was found that while the bis(pyrrolidinylmethyl)phenol pattern of changrolin appeared to be optimal in this series, a wide latitude existed for the heteroaryl substituent for maintaining good antiarrhythmic activity. Further, the antiarrhythmic and parasympatholytic activities tended to exhibit parallel changes.

  DOI：

  10.1021/jm00360a005
• 作为产物：
  描述：

  4-氯喹唑啉 、 3-氨基苯酚 以 乙醇 为溶剂， 反应 2.0h， 以85%的产率得到4-(3-hydroxyphenylamino)-quinazoline
  参考文献：
  名称：

  Synthesis and antiarrhythmic and parasympatholytic properties of substituted phenols. 1. Heteroarylamine derivatives

  摘要：

  Twenty-four structural derivatives of the antiarrhythmic drug changrolin were synthesized and tested for antiarrhythmic and parasympatholytic activities. It was found that while the bis(pyrrolidinylmethyl)phenol pattern of changrolin appeared to be optimal in this series, a wide latitude existed for the heteroaryl substituent for maintaining good antiarrhythmic activity. Further, the antiarrhythmic and parasympatholytic activities tended to exhibit parallel changes.

  DOI：

  10.1021/jm00360a005

文献信息

• COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS
  申请人：Sugen, Inc.

  公开号：EP0748219B1

  公开（公告）日：2005-04-06
• EP0748219A4
  申请人：——

  公开号：EP0748219A4

  公开（公告）日：1999-06-16
• QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS
  申请人：GPC Biotech AG

  公开号：EP1673346A1

  公开（公告）日：2006-06-28
• Quinazoline derivatives for the treatment of herpesviral infections
  申请人：Herget Thomas

  公开号：US20070123537A1

  公开（公告）日：2007-05-31

  The present invention relates to phenyl-quinazolinyl-amine derivatives and pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising at least one of these derivatives and/or pharmaceutically salts thereof, as well as the use of these derivatives for the prophylaxis and/or treatment of herpesviral induced infections, including opportunistic infections, especially for the prophylaxis and/or treatment of infections and diseases induced by HCMV.
• Methods for Identifying Risk of Type II Diabetes and Treatments Thereof
  申请人：Langdown Maria L.

  公开号：US20080199480A1

  公开（公告）日：2008-08-21

  Provided herein are methods for identifying a risk of type II diabetes in a subject, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating type II diabetes, and therapeutic and preventative methods applicable to type II diabetes. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome.